Axsome Therapeutics Company Profile (NASDAQ:AXSM)

About Axsome Therapeutics (NASDAQ:AXSM)

Axsome Therapeutics logoAxsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AXSM
  • CUSIP: N/A
  • Web: axsome.com
Capitalization:
  • Market Cap: $131.04 million
  • Outstanding Shares: 23,610,000
Average Prices:
  • 50 Day Moving Avg: $5.14
  • 200 Day Moving Avg: $4.68
  • 52 Week Range: $3.53 - $9.11
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.10
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.96 per share
  • Price / Book: 5.78
Profitability:
  • EBIDTA: ($28,750,000.00)
  • Return on Equity: -116.34%
  • Return on Assets: -74.68%
Debt:
  • Debt-to-Equity Ratio: 0.35%
  • Current Ratio: 4.73%
  • Quick Ratio: 4.73%
Misc:
  • Average Volume: 213,656 shs.
  • Beta: 1.03
  • Short Ratio: 4.52
 

Frequently Asked Questions for Axsome Therapeutics (NASDAQ:AXSM)

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.01. View Axsome Therapeutics' Earnings History.

When will Axsome Therapeutics make its next earnings announcement?

Axsome Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for Axsome Therapeutics.

Where is Axsome Therapeutics' stock going? Where will Axsome Therapeutics' stock price be in 2017?

5 equities research analysts have issued 12-month price objectives for Axsome Therapeutics' shares. Their predictions range from $13.00 to $31.00. On average, they anticipate Axsome Therapeutics' share price to reach $19.60 in the next year. View Analyst Ratings for Axsome Therapeutics.

What are analysts saying about Axsome Therapeutics stock?

Here are some recent quotes from research analysts about Axsome Therapeutics stock:

  • 1. According to Zacks Investment Research, "Axsome Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing novel therapies for the management of pain and other central nervous system disorders. Its product candidate portfolio consists of AXS-02 and AXS-05 which are in clinical trial stage. Axsome Therapeutics, Inc. is based in New York. " (9/22/2017)
  • 2. Aegis analysts commented, "We believe Ms. Potter’s prior experience adds value to the Board of Directors for Axsome. Her career in healthcare spans more than 30 years with multiple leadership positions at several large pharmaceutical companies. As Axsome looks to report multiple phase III interim analysis and topline readouts over the next 24 months, her experience in the commercialization process should go a long way for management. Myrtle Potter – Prior experience. After starting her career with Procter and Gamble Patient Care Products, Ms. Potter went on to spend 14 years of her early career at Merck & Co. While holding positions of increasing responsibility at Merck, she started Astra Merck, a joint venture entity that later became AstraZeneca, and served as Vice President of Merck’s US pharmaceutical business unit with about $800 mil revenue. Ms. Potter also served as President of Bristol-Myers Squibb’s US Cardiovascular and Metabolic Business – a 3,500 person business segment with $3.5 billion annual revenue – for 4 years. From 2000 to 2005 she was President, Commercial Operations and Chief Operating Officer at Genentech. While at Genentech, Ms. Potter led the commercialization of a long list of products: Herceptin, Tarceva, Xolair, Avastin, Rituxan, Nutropin, Activase, and TNkase." (6/20/2017)

Who are some of Axsome Therapeutics' key competitors?

Who are Axsome Therapeutics' key executives?

Axsome Therapeutics' management team includes the folowing people:

  • Herriot Tabuteau M.D., Chairman of the Board, Chief Executive Officer
  • John Golubieski, Chief Financial Officer
  • Constance Ames, Vice President - Finance
  • Mark Jacobson, Senior Director - Operations
  • Randall E. Kaye M.D., Chief Medical Officer
  • Robert Niecestro Ph.D., Head of Regulatory
  • Mark Coleman M.D., Independent Director
  • Roger A. Jeffs Ph.D., Independent Director
  • Myrtle S. Potter, Independent Director
  • Mark Saad, Independent Director

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager.

Who owns Axsome Therapeutics stock?

Axsome Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (7.38%), JPMorgan Chase & Co. (6.08%), Royce & Associates LP (3.73%), Sphera Funds Management LTD. (2.12%), Stifel Financial Corp (1.76%) and Vanguard Group Inc. (1.17%). View Institutional Ownership Trends for Axsome Therapeutics.

Who sold Axsome Therapeutics stock? Who is selling Axsome Therapeutics stock?

Axsome Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Northern Trust Corp, Vanguard Group Inc., FMR LLC and Mariner Wealth Advisors LLC. View Insider Buying and Selling for Axsome Therapeutics.

Who bought Axsome Therapeutics stock? Who is buying Axsome Therapeutics stock?

Axsome Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., LMR Partners LLP, Goldman Sachs Group Inc. and Susquehanna International Group LLP. View Insider Buying and Selling for Axsome Therapeutics.

How do I buy Axsome Therapeutics stock?

Shares of Axsome Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Axsome Therapeutics' stock price today?

One share of Axsome Therapeutics stock can currently be purchased for approximately $5.55.


MarketBeat Community Rating for Axsome Therapeutics (NASDAQ AXSM)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  105 (Vote Outperform)
Underperform Votes:  66 (Vote Underperform)
Total Votes:  171
MarketBeat's community ratings are surveys of what our community members think about Axsome Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Axsome Therapeutics (NASDAQ:AXSM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.60 (253.15% upside)

Analysts' Ratings History for Axsome Therapeutics (NASDAQ:AXSM)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/26/2017Ladenburg Thalmann Financial ServicesReiterated RatingBuy$28.00 -> $31.00HighView Rating Details
6/20/2017AegisReiterated RatingBuy$20.00HighView Rating Details
5/19/2017BTIG ResearchInitiated CoverageBuy$14.00HighView Rating Details
3/8/2017Cantor FitzgeraldSet Price TargetBuy$13.00LowView Rating Details
10/3/2016Brean CapitalInitiated CoverageBuy$20.00N/AView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for Axsome Therapeutics (NASDAQ:AXSM)
Earnings by Quarter for Axsome Therapeutics (NASDAQ:AXSM)
Earnings History by Quarter for Axsome Therapeutics (NASDAQ AXSM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017($0.34)N/AView Earnings Details
8/9/2017Q2 2017($0.31)($0.30)ViewN/AView Earnings Details
5/9/20173/31/2017($0.40)($0.41)ViewN/AView Earnings Details
11/14/2016Q3($0.39)($0.38)ViewN/AView Earnings Details
8/9/2016Q2 2016($0.39)($0.36)ViewN/AView Earnings Details
5/11/2016Q116($0.28)($0.31)ViewN/AView Earnings Details
3/24/2016Q416($0.22)($0.12)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Axsome Therapeutics (NASDAQ:AXSM)
Current Year EPS Consensus Estimate: $-1.38 EPS
Next Year EPS Consensus Estimate: $-0.91 EPS

Dividends

Dividend History for Axsome Therapeutics (NASDAQ:AXSM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Axsome Therapeutics (NASDAQ:AXSM)
Insider Ownership Percentage: 35.20%
Institutional Ownership Percentage: 27.12%
Insider Trades by Quarter for Axsome Therapeutics (NASDAQ:AXSM)
Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)
Insider Trades by Quarter for Axsome Therapeutics (NASDAQ:AXSM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/23/2015Randall KayeInsiderBuy1,000$9.03$9,030.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Axsome Therapeutics (NASDAQ:AXSM)
Latest Headlines for Axsome Therapeutics (NASDAQ:AXSM)
Source:
DateHeadline
americanbankingnews.com logoAxsome Therapeutics, Inc. (AXSM) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - September 22 at 5:12 PM
americanbankingnews.com logoAxsome Therapeutics, Inc. (AXSM) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - September 12 at 8:52 PM
streetinsider.com logoAxsome Therapeutics (AXSM) Reports CREATE-1 Interim Analysis Expected Year-End 2017
www.streetinsider.com - September 8 at 4:43 PM
finance.yahoo.com logoAxsome reports 2Q loss
finance.yahoo.com - September 7 at 4:20 PM
finance.yahoo.com logoAxsome Announces CREATE-1 Interim Analysis Expected Year-End 2017
finance.yahoo.com - September 7 at 4:20 PM
americanbankingnews.com logoAxsome Therapeutics, Inc. (AXSM) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - September 6 at 2:28 AM
americanbankingnews.com logoAxsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 12 at 2:32 AM
americanbankingnews.com logoAxsome Therapeutics, Inc. (AXSM) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - August 10 at 3:42 PM
globenewswire.com logoAxsome Therapeutics Reports Second Quarter 2017 Financial Results
globenewswire.com - August 9 at 4:27 PM
americanbankingnews.com logoAxsome Therapeutics, Inc. (AXSM) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - July 31 at 8:05 AM
americanbankingnews.com logoAxsome Therapeutics' (AXSM) Buy Rating Reaffirmed at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - July 26 at 12:40 PM
finance.yahoo.com logoAxsome Therapeutics Announces AXS-06 (MoSEIC™ Meloxicam and Esomeprazole) Meets Primary Endpoint in Phase 1 Clinical Trial
finance.yahoo.com - July 25 at 4:09 PM
americanbankingnews.com logoAxsome Therapeutics, Inc. (AXSM) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 18 at 1:53 PM
finance.yahoo.com logoAxsome Therapeutics Initiates Phase 2/3 Trial of AXS-05 for Alzheimer’s Disease Agitation
finance.yahoo.com - July 17 at 4:37 PM
americanbankingnews.com logoAxsome Therapeutics, Inc. (AXSM) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - July 13 at 7:14 PM
feeds.benzinga.com logoAxsome Therapeutics Appoints John Golubieski as Chief Financial Officer
feeds.benzinga.com - July 6 at 7:38 AM
finance.yahoo.com logoWill Axsome Therapeutics (AXSM) Continue to Surge Higher?
finance.yahoo.com - June 22 at 11:55 AM
americanbankingnews.com logoAxsome Therapeutics, Inc. (AXSM) Upgraded at ValuEngine
www.americanbankingnews.com - June 21 at 10:38 PM
americanbankingnews.com logoAxsome Therapeutics, Inc. (AXSM) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 21 at 4:42 PM
americanbankingnews.com logoZacks: Axsome Therapeutics, Inc. (AXSM) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - June 21 at 7:50 AM
americanbankingnews.com logoAxsome Therapeutics, Inc. (AXSM) Earns Buy Rating from Aegis
www.americanbankingnews.com - June 20 at 8:38 AM
americanbankingnews.com logoZacks Investment Research Upgrades Axsome Therapeutics, Inc. (AXSM) to "Buy"
www.americanbankingnews.com - June 19 at 5:04 PM
finance.yahoo.com logoAxsome Therapeutics Appoints Myrtle Potter to its Board of Directors
finance.yahoo.com - June 19 at 9:56 AM
americanbankingnews.com logoAxsome Therapeutics Inc (AXSM) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - June 5 at 4:22 PM
americanbankingnews.com logoAxsome Therapeutics Inc (AXSM) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - June 2 at 6:18 PM
americanbankingnews.com logoAxsome Therapeutics Inc (AXSM) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 26 at 4:40 PM
americanbankingnews.com logoAxsome Therapeutics Inc (AXSM) Receives "Buy" Rating from Aegis
www.americanbankingnews.com - May 25 at 7:48 AM
americanbankingnews.com logoAxsome Therapeutics Inc (AXSM) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - May 24 at 5:46 PM
americanbankingnews.com logoBTIG Research Initiates Coverage on Axsome Therapeutics Inc (AXSM)
www.americanbankingnews.com - May 19 at 9:34 AM
americanbankingnews.com logoAxsome Therapeutics Inc (AXSM) Forecasted to Post FY2017 Earnings of ($1.33) Per Share
www.americanbankingnews.com - May 15 at 8:52 AM
americanbankingnews.com logoAxsome Therapeutics Inc (AXSM) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - May 10 at 10:22 PM
marketbeat.com logoAxsome reports 1Q loss
marketbeat.com - May 9 at 9:56 AM
globenewswire.com logoAxsome Therapeutics Reports First Quarter 2017 Financial Results
globenewswire.com - May 9 at 9:05 AM
streetinsider.com logoAxsome Therapeutics (AXSM) Receives FDA Fast Track Designation for AXS-05 for AD Agitation
www.streetinsider.com - May 8 at 3:40 PM
finance.yahoo.com logoAxsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Alzheimer’s Disease Agitation
finance.yahoo.com - May 8 at 10:44 AM
americanbankingnews.com logoAxsome Therapeutics Inc (AXSM) to Release Earnings on Tuesday
www.americanbankingnews.com - May 7 at 7:12 AM
americanbankingnews.com logoAxsome Therapeutics (AXSM) Getting Positive News Coverage, Analysis Shows
www.americanbankingnews.com - May 4 at 7:58 AM
americanbankingnews.com logoShort Interest in Axsome Therapeutics Inc (AXSM) Rises By 69.5%
www.americanbankingnews.com - May 4 at 1:01 AM
americanbankingnews.com logoAxsome Therapeutics (AXSM) Earning Somewhat Favorable Press Coverage, Report Shows
www.americanbankingnews.com - May 1 at 12:42 PM
americanbankingnews.com logoAxsome Therapeutics (AXSM) Earning Positive News Coverage, Report Shows
www.americanbankingnews.com - April 27 at 4:42 PM
americanbankingnews.com logoAxsome Therapeutics (AXSM) Earns Daily Media Sentiment Rating of 0.01
www.americanbankingnews.com - April 24 at 6:02 PM
americanbankingnews.com logoAxsome Therapeutics (AXSM) Earns Daily News Impact Score of 0.22
www.americanbankingnews.com - April 19 at 7:47 AM
americanbankingnews.com logoAxsome Therapeutics (AXSM) Receiving Somewhat Positive Media Coverage, Report Finds
www.americanbankingnews.com - April 16 at 7:26 AM
americanbankingnews.com logoAxsome Therapeutics Inc (AXSM) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 24 at 7:22 PM
americanbankingnews.com logo Axsome Therapeutics Inc (AXSM) Given $20.33 Consensus Target Price by Brokerages
www.americanbankingnews.com - March 24 at 11:55 AM
finance.yahoo.com logoAxsome Therapeutics to Present at the 16th Annual Needham Healthcare Conference
finance.yahoo.com - March 23 at 4:12 PM
americanbankingnews.com logoCantor Fitzgerald Weighs in on Axsome Therapeutics Inc's FY2017 Earnings (AXSM)
www.americanbankingnews.com - March 23 at 9:32 AM
americanbankingnews.com logoAxsome Therapeutics Inc (AXSM) Stock Rating Reaffirmed by Aegis
www.americanbankingnews.com - March 23 at 8:53 AM
streetinsider.com logoAxsome Therapeutics (AXSM) Announces 3.74M Share Pricing at $3.74
www.streetinsider.com - March 21 at 9:11 PM
us.rd.yahoo.com logoAxsome Therapeutics Announces Proposed Public Offering of Common Stock
us.rd.yahoo.com - March 21 at 4:09 PM

Social

Chart

Axsome Therapeutics (AXSM) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff